Test-retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction models,Alzheimer's & Dementia

当前位置： X-MOL 学术 › Alzheimers Dement. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Test-retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction models
Alzheimer's & Dementia ( IF 13.0 ) Pub Date : 2022-06-14 , DOI: 10.1002/alz.12706
Nicholas C Cullen ₁ , Shorena Janelidze ₁ , Niklas Mattsson-Carlgren _{1,

2,

3} , Sebastian Palmqvist _{1,

4} , Tobias Bittner ₅ , Ivonne Suridjan ₆ , Alexander Jethwa ₇ , Gwendlyn Kollmorgen ₇ , Wagner S Brum ₈ , Henrik Zetterberg _{9,

10,

11,

12,

13} , Kaj Blennow _{9,

10} , Erik Stomrud _{1,

4} , Oskar Hansson _{1,

4}

Affiliation

Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Faculty of Medicine, Lund University, Lund, Sweden.
Department of Neurology, Skåne University Hospital, Lund, Sweden.
Wallenberg Center for Molecular Medicine, Lund University, Lund, Sweden.
Memory Clinic, Skåne University Hospital, Malmö, Sweden.
F. Hoffmann-La Roche Ltd, Basel, Switzerland.
Roche Diagnostics International Ltd, Rotkreuz, Switzerland.
Roche Diagnostics GmbH, Penzberg, Germany.
Graduate Program in Biological Sciences: Biochemistry, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil.
Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.
Department of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London, UK.
UK Dementia Research Institute at UCL, London, UK.
Hong Kong Center for 27 Neurodegenerative Diseases, Hong Kong, China.

The effect of random error on the performance of blood-based biomarkers for Alzheimer's disease (AD) must be determined before clinical implementation.

中文翻译：